Market cap
$12,599 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
10
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -93.85 | -- | -- |
| EBIT | 5.19 | -51.84 | -71.06 | -273.64 | -300.30 |
| Net Profit | 4.45 | -49.35 | -57.65 | -260.81 | -285.74 |
| EPS | 1.86 | -29.17 | -32.01 | -233.18 | -- |
| Book Value | -- | -- | -3.68 | 37.51 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-23 | Dec-22 | Dec-21 |
| EBIT-Margin
| -26,255.48 | -26,255.48 | -75,653.98 | -2,723.29 | -389.17 |
| Net Margin
| -738.31 | -1,183.63 | -- | -1,088.15 | -388.47 |
| Return on equity
| -34.86 | -28.40 | -36.44 | -33.94 | -34.20 |
| Return on Capital
| -34.52 | -28.18 | -36.10 | -33.68 | -33.79 |
| Return on Assets
| -33.41 | -27.45 | -34.70 | -32.68 | -32.86 |
| Debt to Equity (x)
| -- | -- | 0.01 | 0.00 | 0.01 |
Profitability
ROCE
-36.10
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-36.10
|
-33.68
|
-33.79
|
-18.74
|
-18.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-36.44
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-36.44
|
-33.94
|
-34.20
|
-18.81
|
-18.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-34.70
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-34.70
|
-32.68
|
-32.86
|
-18.51
|
-18.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-75,653.98
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-75,653.98
|
-2,723.29
|
-389.17
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-66,311.93
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-66,311.93
|
-1,088.15
|
-388.47
|
-2,074.25
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-0.94
--
Year on year growth in net sales
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-0.94
|
-0.71
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-70.80
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-70.80
|
-101.37
|
-100.31
|
-58.17
|
-213.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-56.94
--
Year on year growth in profit after tax
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-56.94
|
-92.16
|
-109.77
|
-52.87
|
-156.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-0.36
--
Year on year growth in earnings per share
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-0.36
|
-0.74
|
-0.88
|
0.29
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.01
--
Total debt / Net worth
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
0.01
|
0.00
|
0.01
|
0.01
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
19.31
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
19.31
|
34.02
|
25.59
|
50.28
|
132.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
18.82
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
18.82
|
33.18
|
24.56
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
--
|
-20.43
|
-1,013.05
|
-495.28
|
-48.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
749.24
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
749.24
|
0.54
|
4.73
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
--
Sales / Average Total Assets
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
0.00
|
0.01
|
0.08
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
1,384.21
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
1,384.21
|
31.02
|
8.65
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
6,565.91
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
6,565.91
|
8,081.81
|
15,075.59
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
983.66
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
983.66
|
709.15
|
1,012.02
|
1,778.39
|
2,569.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
6,966.46
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
6,966.46
|
7,403.69
|
14,072.21
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-27.00
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-27.00
|
-22.75
|
-26.42
|
-38.53
|
-20.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
9.34
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
9.34
|
5.58
|
7.57
|
7.79
|
2.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-21.22
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
-21.22
|
-17.91
|
-23.14
|
-33.89
|
-12.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|